Gem Aromatics Q1FY27 Results: Navigating Costs Amidst Expansion

Consolidated PAT: -7.9 Cr | Consolidated Revenue: 98.9 Cr

Reader Takeaway: Revenue grows, but new capex and costs lead to a consolidated loss; watch Krystal pipeline.

What just happened

Gem Aromatics Ltd. announced its financial results for the first quarter of FY27 (ended June 30, 2026). The company reported a consolidated net loss of Rs 7.9 crore, a significant shift from a profit of Rs 8.0 crore in the same quarter last year. Standalone revenue from operations grew by 8.6% to Rs 83.0 crore from Rs 76.4 crore in Q1FY26. However, consolidated revenue saw a larger increase of 12.8% to Rs 98.9 crore.

Why this matters

The swing to a consolidated loss highlights the immediate financial impact of recent capital expenditures. Increased depreciation from the new Dahej facility and higher raw material costs, particularly from supply chain issues in Madagascar, put pressure on profitability. Investors will be watching to see if the company can leverage its expanded capacity and new product pipeline to improve margins.

The backstory

Gem Aromatics has been investing in expanding its manufacturing capabilities, including a significant capital expenditure of approximately Rs 265 crore for its Dahej facility. This expansion is aimed at increasing production capacity and diversifying its product portfolio through subsidiaries like Krystal Ingredients.

What changes now

The company is focused on utilizing its new Dahej plant and commercializing new products from Krystal Ingredients, including cooling agents, safranal, and phenol derivatives. International expansion with a wholly owned subsidiary in Brazil is also planned to boost distribution.

Risks to watch

The primary concern is the company's ability to improve consolidated margins and profitability. Successfully scaling up the Dahej facility, securing customer approvals for new products, and normalizing raw material costs are critical. The seasonal nature of the business and potential supply chain disruptions remain watch points.

Peer comparison

While specific peer data is not provided in the filing, the challenges faced by Gem Aromatics in managing raw material costs and depreciation due to capex are common in the specialty chemicals and aromatics sectors as companies expand.

Context metrics (time-bound)

• Standalone Revenue from Operations: Rs 83.0 Cr (Q1FY27) vs Rs 76.4 Cr (Q1FY26), up 8.6%.
• Consolidated Revenue from Operations: Rs 98.9 Cr (Q1FY27) vs Rs 87.6 Cr (Q1FY26), up 12.8%.
• Standalone EBITDA: Rs 8.5 Cr (Q1FY27) vs Rs 10.5 Cr (Q1FY26), down 19.0%.
• Consolidated EBITDA: Rs 3.3 Cr (Q1FY27) vs Rs 14.9 Cr (Q1FY26), down 77.7%.
• Standalone PAT: Rs 7.3 Cr (Q1FY27) vs Rs 6.5 Cr (Q1FY26), up 11.0%.
• Consolidated PAT: -Rs 7.9 Cr (Q1FY27) vs Rs 8.0 Cr (Q1FY26), a loss.
• Depreciation costs increased to Rs 9.1 crore.

What to track next

Investors should closely monitor the progress of Krystal Ingredients' product launches and their revenue contribution, the ramp-up of the Dahej facility's utilization, and the subsequent improvement in consolidated EBITDA and PAT margins. The normalization of Clove business supply chain issues is also important.